- Home
- MGRM vs AGEN Comparison
MGRM vs AGEN Comparison
Compare MGRM & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- AGEN
- Stock Information
- Founded
- MGRM 2016
- AGEN 1994
- Country
- MGRM United States
- AGEN United States
- Employees
- MGRM N/A
- AGEN N/A
- Industry
- MGRM Medical/Dental Instruments
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGRM Health Care
- AGEN Health Care
- Exchange
- MGRM Nasdaq
- AGEN Nasdaq
- Market Cap
- MGRM 79.9M
- AGEN 87.7M
- IPO Year
- MGRM N/A
- AGEN 2000
- Fundamental
- Price
- MGRM $5.83
- AGEN $6.22
- Analyst Decision
- MGRM Strong Buy
- AGEN Buy
- Analyst Count
- MGRM 1
- AGEN 4
- Target Price
- MGRM $5.40
- AGEN $13.00
- AVG Volume (30 Days)
- MGRM 810.3K
- AGEN 1.5M
- Earning Date
- MGRM 08-13-2025
- AGEN 08-07-2025
- Dividend Yield
- MGRM N/A
- AGEN N/A
- EPS Growth
- MGRM N/A
- AGEN N/A
- EPS
- MGRM N/A
- AGEN N/A
- Revenue
- MGRM N/A
- AGEN $99,524,000.00
- Revenue This Year
- MGRM N/A
- AGEN $12.69
- Revenue Next Year
- MGRM N/A
- AGEN N/A
- P/E Ratio
- MGRM N/A
- AGEN N/A
- Revenue Growth
- MGRM N/A
- AGEN N/A
- 52 Week Low
- MGRM $1.92
- AGEN $1.38
- 52 Week High
- MGRM $6.02
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- MGRM 93.59
- AGEN 59.02
- Support Level
- MGRM $2.81
- AGEN $4.78
- Resistance Level
- MGRM $6.02
- AGEN $7.34
- Average True Range (ATR)
- MGRM 0.19
- AGEN 0.70
- MACD
- MGRM 0.29
- AGEN 0.12
- Stochastic Oscillator
- MGRM 94.70
- AGEN 62.67
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).